Container Closure Delivery System
The present invention relates to a container closure delivery system that is suitable for lyophilized pharmaceutical injectable powder products. The system comprises storage stable powder formulations and a container closure assembly design wherein the formulation can be filled and lyophilized with a standard fill finish equipment, and the formulations and lyophilization processes are optimized to produce a powder that readily dissolves upon contact with a diluent, thereby facilitating the direct injection of the lyophilized product without the need for a separate reconstitution/mixing/priming step.
1 . A container closure delivery system suitable for stable storage of a lyophilized pharmaceutical injectable product, wherein the lyophilized pharmaceutical injectable product is dissolved into a liquid diluent without the need for a reconstitution mixing step.
2 . The container closure delivery system of claim 1 , wherein the lyophilized pharmaceutical injectable product is a storage stable powder formulation of a pharmaceutical product.
3 . The container closure deliver system of claim 1 , wherein the reconstitution of the lyophilized pharmaceutical product is through rapid dissolution, and further wherein, the lyophilized pharmaceutical injectable product is dissolved upon contact with the liquid diluent.
4 . The container closure delivery system of claim 1 , wherein the lyophilized pharmaceutical injectable product comprises an active ingredient and a stabilizer.
5 . The lyophilized pharmaceutical injectable product of claim 4 , wherein the lyophilized pharmaceutical injectable product further includes at least one of the following: a bulking agent, a surfactant and a buffer.
6 . The container closure delivery system of claim 4 , wherein the active ingredient is selected from a small molecule, a vaccine, live or attenuated cells, an oligonucleotide, DNA, a peptide and a recombinant or naturally occurring protein.
7 . The recombinant or naturally occurring protein of claim 6 , wherein the protein is sourced from a human or non-human animal.
8 . The recombinant or naturally occurring protein of claim 6 , wherein the protein is a peptide, polypeptide, consensus molecule, analog, derivative or combinations thereof.
9 . The active ingredient of claim 4 , wherein the active ingredient is useful for prophylactic, therapeutic or diagnostic application.
10 . The active ingredient of claim 4 , wherein the active ingredient is selected from insulin, gastrin, prolactin, adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), motilin, interferons (alpha, beta, gamma), interleukins (IL-1 to IL-12), interleukin-1 receptor antagonists (IL-1ra), tumor necrosis factor (TNF), tumor necrosis factor-binding protein (TNF-bp), erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), stem cell factor (SCF), leptin (OB protein), brain derived neurotrophic factor (BDNF), glial derived neurotrophic factor (GDNF), neurotrophic factor 3 (NT3), fibroblast growth factors (FGF), neurotrophic growth factor (NGF), bone growth factors such as osteoprotegerin (OPG), insulin-like growth factors (IGFs), macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), megakaryocyte derived growth factor (MGDF), keratinocyte growth factor (KGF), thrombopoietin, platelet-derived growth factor (PGDF), novel erythropoiesis stimulating protein (NESP), bone morphogenetic protein (BMP), superoxide dismutase (SOD), tissue plasminogen activator (TPA), urokinase, streptokinase and kallikrein.
11 . The liquid diluent of claim 1 , wherein the liquid diluent is selected from water for injection, bacteriostatic water for injection or phosphate buffered saline.
12 . A container closure delivery system suitable for stable storage of a lyophilized pharmaceutical injectable product, wherein the lyophilized pharmaceutical injectable product is dissolved into a liquid diluent without the need for a reconstitution mixing and priming step.
13 . The container closure delivery system of claim 12 , wherein the lyophilized pharmaceutical injectable product is a storage stable powder formulation of a pharmaceutical product.
14 . The container closure deliver system of claim 12 , wherein the reconstitution of the lyophilized pharmaceutical product is through rapid dissolution, and further wherein, the lyophilized pharmaceutical injectable product is dissolved upon contact with the liquid diluent.
15 . The container closure delivery system of claim 12 , wherein the lyophilized pharmaceutical injectable product comprises an active ingredient and a stabilizer.
16 . The lyophilized pharmaceutical injectable product of claim 15 , wherein the lyophilized pharmaceutical injectable product further includes at least one of the following: a bulking agent, a surfactant and a buffer.
17 . The container closure delivery system of claim 15 , wherein the active ingredient is selected from a small molecule, a vaccine, live or attenuated cells, an oligonucleotide, DNA, a peptide and a recombinant or naturally occurring protein.
18 . The recombinant or naturally occurring protein of claim 17 , wherein the protein is sourced from a human or non-human animal.
19 . The recombinant or naturally occurring protein of claim 17 , wherein the protein is a peptide, polypeptide, consensus molecule, analog, derivative or combinations thereof.
20 . The active ingredient of claim 15 , wherein the active ingredient is useful for prophylactic, therapeutic or diagnostic application.
21 . The active ingredient of claim 15 , wherein the active ingredient is selected from insulin, gastrin, prolactin, adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), motilin, interferons (alpha, beta, gamma), interleukins (IL-1 to IL-12), interleukin-1 receptor antagonists (IL-1ra), tumor necrosis factor (TNF), tumor necrosis factor-binding protein (TNF-bp), erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), stem cell factor (SCF), leptin (OB protein), brain derived neurotrophic factor (BDNF), glial derived neurotrophic factor (GDNF), neurotrophic factor 3 (NT3), fibroblast growth factors (FGF), neurotrophic growth factor (NGF), bone growth factors such as osteoprotegerin (OPG), insulin-like growth factors (IGFs), macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), megakaryocyte derived growth factor (MGDF), keratinocyte growth factor (KGF), thrombopoietin, platelet-derived growth factor (PGDF), novel erythropoiesis stimulating protein (NESP), bone morphogenetic protein (BMP), superoxide dismutase (SOD), tissue plasminogen activator (TPA), urokinase, streptokinase and kallikrein.
22 . The liquid diluent of claim 12 , wherein the liquid diluent is selected from water for injection, bacteriostatic water for injection or phosphate buffered saline.
23 . A method to reconstitute a lyophilized pharmaceutical injectable product, wherein the lyophilized pharmaceutical injectable product is a stored in a container closure delivery system, and further wherein, reconstitution occurs without a mixing or a priming step.
24 . The method of claim 23 , wherein the lyophilized pharmaceutical injectable product is a storage stable powder formulation of a pharmaceutical product.
25 . The method of claim 23 , wherein the reconstitution of the lyophilized pharmaceutical product is through rapid dissolution, and further wherein, the lyophilized pharmaceutical injectable product is dissolved upon contact with the liquid diluent.
26 . The method of claim 23 , wherein the lyophilized pharmaceutical injectable product comprises an active ingredient and a stabilizer.
27 . The method of claim 26 , wherein the active ingredient is selected from a small molecule, a vaccine, live or attenuated cells, an oligonucleotide, DNA, a peptide and a recombinant or naturally occurring protein.
28 . The method of claim 26 , wherein the active ingredient is selected from a small molecule, a vaccine, live or attenuated cells, an oligonucleotide, DNA, a peptide and a recombinant or naturally occurring protein.
29 . The method of claim 26 , wherein the active ingredient is useful for prophylactic, therapeutic or diagnostic application.